129 related articles for article (PubMed ID: 36689696)
1. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
Drogan CM; Kindler HL; Gao G; Kupfer SS
JCO Precis Oncol; 2023 Jan; 7():e2200196. PubMed ID: 36689696
[TBL] [Abstract][Full Text] [Related]
2. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
3. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
4. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma.
Klatte DCF; Starr JS; Clift KE; Hardway HD; van Hooft JE; van Leerdam ME; Potjer TP; Presutti RJ; Riegert-Johnson DL; Wallace MB; Bi Y
JCO Oncol Pract; 2024 Apr; ():OP2300447. PubMed ID: 38621197
[TBL] [Abstract][Full Text] [Related]
5. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
7. Identification of genetic risk for pancreatic adenocarcinoma.
Flores K; Dinh K; Rouleau E; Whalen G; Wassef W; LaFemina J
Cancer Genet; 2015 Nov; 208(11):559-63. PubMed ID: 26481832
[TBL] [Abstract][Full Text] [Related]
8. Evaluating implementation of NCCN guideline-directed genetic screening recommendations for patients with pancreatic ductal adenocarcinoma.
Ghosh AK; Bhushan S; Abidoye O; Robinson SS; Rynarzewska AI; Sampat D
Cancer Causes Control; 2024 Apr; 35(4):679-684. PubMed ID: 38015388
[TBL] [Abstract][Full Text] [Related]
9. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract][Full Text] [Related]
11. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
[TBL] [Abstract][Full Text] [Related]
12. Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical Perspective.
Copur MS; Talmon GA; Wedel W; Hart JD; Merani S; Vargasi LM
Oncology (Williston Park); 2020 Jun; 34(6):196-201. PubMed ID: 32609864
[TBL] [Abstract][Full Text] [Related]
13. Risk perception and surveillance uptake in individuals at increased risk for pancreatic ductal adenocarcinoma.
Nguyen D; Gilad O; Drogan CM; Eilers Z; Liao C; Kupfer SS
J Med Genet; 2024 Feb; 61(3):270-275. PubMed ID: 37852748
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
Mohindroo C; De Jesus-Acosta A; Yurgelun MB; Maitra A; Mork M; McAllister F
Surg Pathol Clin; 2022 Sep; 15(3):491-502. PubMed ID: 36049831
[TBL] [Abstract][Full Text] [Related]
15. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
16. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
17. Inherited predisposition to pancreatic cancer.
Hilfrank KJ; Rustgi SD; Kastrinos F
Semin Oncol; 2021 Feb; 48(1):2-9. PubMed ID: 33773812
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Power R; Leavy C; Nolan C; White N; Clarke R; Cadoo KA; Gallagher DJ; Lowery MA
Fam Cancer; 2021 Apr; 20(2):97-101. PubMed ID: 32918181
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.
Rodriguez NJ; Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Fortes I; Caruso A; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Zhou AY; Coffin TB; Uno H; Horiguchi M; Ocean AJ; McAllister F; Lowy AM; Klein AP; Madlensky L; Petersen GM; Garber JE; Lippman SM; Goggins MG; Maitra A; Syngal S
Gastroenterology; 2024 May; 166(5):872-885.e2. PubMed ID: 38320723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]